PL3389717T3 - Terapia neoadjuwantowa raka pęcherza moczowego - Google Patents
Terapia neoadjuwantowa raka pęcherza moczowegoInfo
- Publication number
- PL3389717T3 PL3389717T3 PL16819894.3T PL16819894T PL3389717T3 PL 3389717 T3 PL3389717 T3 PL 3389717T3 PL 16819894 T PL16819894 T PL 16819894T PL 3389717 T3 PL3389717 T3 PL 3389717T3
- Authority
- PL
- Poland
- Prior art keywords
- bladder cancer
- neoadjuvant therapy
- neoadjuvant
- therapy
- bladder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
- A61N5/0603—Apparatus for use inside the body for treatment of body cavities
- A61N2005/061—Bladder and/or urethra
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0626—Monitoring, verifying, controlling systems and methods
- A61N2005/0629—Sequential activation of light sources
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0662—Visible light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0662—Visible light
- A61N2005/0663—Coloured light
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Radiology & Medical Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1522309.2A GB201522309D0 (en) | 2015-12-17 | 2015-12-17 | Use |
| PCT/EP2016/081803 WO2017103283A1 (en) | 2015-12-17 | 2016-12-19 | Neoadjuvant therapy for bladder cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3389717T3 true PL3389717T3 (pl) | 2025-06-09 |
Family
ID=55311159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16819894.3T PL3389717T3 (pl) | 2015-12-17 | 2016-12-19 | Terapia neoadjuwantowa raka pęcherza moczowego |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10556010B2 (enExample) |
| EP (1) | EP3389717B9 (enExample) |
| JP (1) | JP6926086B2 (enExample) |
| KR (1) | KR102787188B1 (enExample) |
| CN (2) | CN119345359A (enExample) |
| AU (1) | AU2016372573B2 (enExample) |
| BR (1) | BR112018012009B1 (enExample) |
| DK (1) | DK3389717T3 (enExample) |
| ES (1) | ES3015668T3 (enExample) |
| FI (1) | FI3389717T3 (enExample) |
| GB (1) | GB201522309D0 (enExample) |
| PL (1) | PL3389717T3 (enExample) |
| WO (1) | WO2017103283A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201522311D0 (en) * | 2015-12-17 | 2016-02-03 | Photocure Asa | Use |
| GB201522309D0 (en) * | 2015-12-17 | 2016-02-03 | Photocure Asa | Use |
| CA3079496C (en) * | 2017-12-01 | 2021-06-01 | Sbi Pharmaceuticals Co., Ltd. | Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor |
| KR102441358B1 (ko) | 2020-09-14 | 2022-09-06 | 주식회사 아파트엔 | 아파트의 지수화를 통한 아파트 투자 가치 평가 시스템 |
| WO2024184417A1 (en) | 2023-03-07 | 2024-09-12 | Photocure Asa | Therapy for bladder cancer |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2157424T3 (es) | 1995-03-10 | 2001-08-16 | Photocure Asa | Esteres de acido 5-aminolevulinico como agentes fotosensibilizantes en fotoquimioterapia. |
| US7530461B2 (en) * | 1995-03-10 | 2009-05-12 | Photocure Asa | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
| GB0018528D0 (en) * | 2000-07-27 | 2000-09-13 | Photocure Asa | Compounds |
| ATE481985T1 (de) | 2002-07-03 | 2010-10-15 | Ono Pharmaceutical Co | Immunpotenzierende zusammensetzungen |
| GB0406917D0 (en) | 2004-03-26 | 2004-04-28 | Photocure Asa | Compounds |
| KR101498834B1 (ko) | 2005-05-09 | 2015-03-05 | 오노 야꾸힝 고교 가부시키가이샤 | 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
| HRP20080053A2 (hr) | 2005-07-01 | 2009-08-31 | Medarex | Ljudska monoklonska protutijela na ligand 1 za programiranu smrt stanice (pd-l1) |
| CN104945508B (zh) | 2007-06-18 | 2019-02-22 | 默沙东有限责任公司 | 针对人程序性死亡受体pd-1的抗体 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| CA3120172A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| SI2440199T1 (sl) | 2009-06-11 | 2016-05-31 | Photocure Asa | Poltrdni sestavki in farmacevtski proizvodi |
| TWI835048B (zh) | 2011-08-01 | 2024-03-11 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
| MX349096B (es) | 2011-11-28 | 2017-07-11 | Merck Patent Gmbh | Anticuerpos anti-pd-l1 y sus usos. |
| SG10201603055WA (en) | 2012-05-31 | 2016-05-30 | Genentech Inc | Methods Of Treating Cancer Using PD-L1 Axis Binding Antagonists And VEGF Antagonists |
| US8927761B2 (en) | 2012-06-28 | 2015-01-06 | Photocure Asa | Form of hexyl-5-aminolevulinate hydrochloride and methods of using the same |
| SG11201500805VA (en) * | 2012-08-03 | 2015-02-27 | Photocure Asa | Compounds |
| GB201522309D0 (en) * | 2015-12-17 | 2016-02-03 | Photocure Asa | Use |
| CN109010850B (zh) * | 2018-08-01 | 2021-10-22 | 上海师范大学 | 一种负载姜黄素的葡聚糖修饰的钆掺杂的空心介孔二氧化硅纳米材料的制备方法及应用 |
-
2015
- 2015-12-17 GB GBGB1522309.2A patent/GB201522309D0/en not_active Ceased
-
2016
- 2016-12-19 EP EP16819894.3A patent/EP3389717B9/en active Active
- 2016-12-19 PL PL16819894.3T patent/PL3389717T3/pl unknown
- 2016-12-19 US US16/063,185 patent/US10556010B2/en active Active
- 2016-12-19 FI FIEP16819894.3T patent/FI3389717T3/fi active
- 2016-12-19 ES ES16819894T patent/ES3015668T3/es active Active
- 2016-12-19 DK DK16819894.3T patent/DK3389717T3/da active
- 2016-12-19 CN CN202411498667.9A patent/CN119345359A/zh active Pending
- 2016-12-19 AU AU2016372573A patent/AU2016372573B2/en active Active
- 2016-12-19 JP JP2018531667A patent/JP6926086B2/ja active Active
- 2016-12-19 BR BR112018012009-0A patent/BR112018012009B1/pt active IP Right Grant
- 2016-12-19 WO PCT/EP2016/081803 patent/WO2017103283A1/en not_active Ceased
- 2016-12-19 KR KR1020187020006A patent/KR102787188B1/ko active Active
- 2016-12-19 CN CN201680079674.2A patent/CN108601836A/zh active Pending
-
2020
- 2020-01-21 US US16/748,332 patent/US11311620B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10556010B2 (en) | 2020-02-11 |
| EP3389717A1 (en) | 2018-10-24 |
| EP3389717B1 (en) | 2025-02-19 |
| RU2018124868A3 (enExample) | 2020-05-13 |
| CN108601836A (zh) | 2018-09-28 |
| KR102787188B1 (ko) | 2025-03-25 |
| CA3008551A1 (en) | 2017-06-22 |
| JP2018537514A (ja) | 2018-12-20 |
| BR112018012009A2 (pt) | 2018-12-04 |
| US20200155683A1 (en) | 2020-05-21 |
| RU2018124868A (ru) | 2020-01-27 |
| DK3389717T3 (da) | 2025-03-31 |
| JP6926086B2 (ja) | 2021-08-25 |
| FI3389717T3 (fi) | 2025-04-08 |
| GB201522309D0 (en) | 2016-02-03 |
| AU2016372573A1 (en) | 2018-07-12 |
| WO2017103283A1 (en) | 2017-06-22 |
| ES3015668T3 (en) | 2025-05-07 |
| CN119345359A (zh) | 2025-01-24 |
| US20180369379A1 (en) | 2018-12-27 |
| US11311620B2 (en) | 2022-04-26 |
| EP3389717B9 (en) | 2025-07-23 |
| KR20180094987A (ko) | 2018-08-24 |
| AU2016372573B2 (en) | 2022-07-21 |
| BR112018012009B1 (pt) | 2023-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271946A (en) | Combination for cancer treatment | |
| IL254705A0 (en) | Combination therapy for cancer | |
| IL259017A (en) | Cancer cure is intended | |
| ZA201702382B (en) | Combination therapy for cancer | |
| IL255060A0 (en) | Combined treatment for cancer | |
| LT3423087T (lt) | Kompleksinė priešvėžinė terapija | |
| LT3197456T (lt) | Vėžio gydymas | |
| IL249898A0 (en) | Combined cancer treatment | |
| IL246761A0 (en) | Combined cancer treatment | |
| IL258671A (en) | A therapeutic agent for breast cancer | |
| PL3389717T3 (pl) | Terapia neoadjuwantowa raka pęcherza moczowego | |
| PL3390448T3 (pl) | Terapia dopęcherzowa raka pęcherza moczowego | |
| GB201519734D0 (en) | Cancer therapy | |
| GB201704909D0 (en) | Cancer therapy | |
| IL259097A (en) | Combination therapy for cancer | |
| GB201711855D0 (en) | Cancer therapy | |
| HRP20210383T8 (hr) | Kombinirana terapija za rak | |
| GB201711250D0 (en) | Cancer therapy | |
| GB201710198D0 (en) | Cancer therapy | |
| GB201706046D0 (en) | Cancer therapy | |
| GB201700772D0 (en) | Cancer therapy | |
| GB201511609D0 (en) | Cancer therapy | |
| GB201511121D0 (en) | Cancer therapy | |
| GB201511120D0 (en) | Cancer therapy | |
| GB201601248D0 (en) | Cancer therapy |